Request Demo

MeMed BV

Now from Whole Blood

Introducing the next generation MeMed BV test
Now FDA cleared in the US to include
whole blood sample type

MeMed BV Whole Blood 
Enhanced Patient Care

Expanded Patient Access

MeMed BV on whole blood expands access to a broader patient population, accelerates our mission of establishing it as the standard of care and opens testing to urgent care centers which see 100 million patients for potential infections in the US annually.

Even Faster Workflow

This new version of MeMed BV retains the exceptional performance of its serum counterpart but eliminates the need for clotting and spinning, making it ideal for decentralized settings like urgent care centers that require minimal handling and maintenance.

Unmatched Performance

MeMed BV performance goals independently confirmed in unprecedented validation and real-world usage encompassing >20,000 patients.1-7

Ground breaking Technology

Accurately measures multiple proteins present in low concentrations within a few minutes, from a small volume of whole blood, delivering actionable results at the point-of-need.

Improved Patient Communication

With the shorter time to results, MeMed BV directly from whole blood can help communicate clinical diagnosis and management decisions to the patients and caregivers, potentially increasing satisfaction and adherence to treatment recommendations.

what we do

Is it a bacterial or viral infection?

Watch the video to learn more…

References

  1. MeMed data on file. Based on secondary endpoint analysis in Apollo Clinical Study (NCT04690569).
  2. Oved K, Cohen A, Boico O, Navon R, Friedman T, Etshtein L, et al. A novel host-proteome signature for distinguishing between acute bacterial and viral infections. PloS One. 2015 Mar 18;10(3):e0120012.
  3. van Houten CB, de Groot JA, Klein A, Srugo I, Chistyakov I, de Waal W, et al. A host-protein based assay to differentiate between bacterial and viral infections in preschool children (OPPORTUNITY): A double-blind, multicentre, validation study. Lancet Infect Dis. 2017 Apr 1;17(4):431-40.
  4. Srugo I, Klein A, Stein M, Golan-Shany O, Kerem N, Chistyakov I, et al. Validation of a novel assay to distinguish bacterial and viral infections. Pediatrics. 2017 Oct 1;140(4).
  5. Ashkenazi-Hoffnung L, Oved K, Navon R, Friedman T, Boico O, Paz M, et al. A host-protein signature is superior to other biomarkers for differentiating between bacterial and viral disease in patients with respiratory infection and fever without source: A prospective observational study. Eur J Clin Microbiol Infect Dis. 2018 Jul;37(7):1361-71.
  6. Stein M, Lipman-Arens S, Oved K, Cohen A, Bamberger E, Navon R, et al. A novel host-protein assay outperforms routine parameters for distinguishing between bacterial and viral lower respiratory tract infections. Diagn Microbiol Infect Dis. 2018 Mar 1;90(3):206-13.
  7. Eden E, Srugo I, Gottlieb T, Navon R, Boico O, Cohen A, et al. Diagnostic accuracy of a TRAIL, IP-10 and CRP combination for discriminating bacterial and viral etiologies at the Emergency Department. J Infect. 2016 Aug 1;73(2):177-80.

MeMed BV from whole blood has been 510K cleared. Currently available only for the US market.